Showing 1 - 4 results of 4 for search 'Laura Clifton‐Hadley', query time: 0.03s Refine Results
  1. 1
    Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.

    Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. by Nicholas Brown, Catherine McBain, Stephen Nash, Kirsten Hopkins, Paul Sanghera, Frank Saran, Mark Phillips, Fiona Dungey, Laura Clifton-Hadley, Katharina Wanek, Daniel Krell, Sarah Jeffries, Iftekhar Khan, Paul Smith, Paul Mulholland

    Published 2016-01-01
    Get full text
    Article
  2. 2
    Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

    Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial by Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrans, Anthony Lawrie, Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton‐Hadley, David C. Linch, Andrew K. McMillan

    Published 2020-07-01
    Get full text
    Article
  3. 3
    An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma

    An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma by Colin Watts, Keyoumars Ashkan, Michael D. Jenkinson, Stephen J. Price, Thomas Santarius, Tomasz Matys, Ting Ting Zhang, Alina Finch, Peter Collins, Kieren Allinson, Sarah J. Jefferies, Daniel J. Scoffings, Athanasios Zisakis, Mark Phillips, Katharina Wanek, Paul Smith, Laura Clifton-Hadley, Nicholas Counsell

    Published 2021-06-01
    Get full text
    Article
  4. 4
    P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma

    P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untre... by John Radford, Toyin Adedayo, Arzhang Ardavan, Sally F. Barrington, Leanne Berkahn, Stephane Chauvie, Laura Clifton-Hadley, Graham P. Collins, Michael Crump, David Cutter, Darren Edwards, Martin Hutchings, Tim Illidge, Amy A. Kirkwood, Kim Linton, Craig H. Moskowitz, Pip Patrick, Beth Phillips, Lois Shepherd, Sanne Tonino, Judith Trotman, Joanna Williams, Nicole Wong Doo

    Published 2022-10-01
    Get full text
    Article

Search Tools: